Safety and Efficacy of Dose-Escalated ¹⁷⁷Lutetium PSMA Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Dose Escalation Study. (EANM 2026) - Sep 29, 2026 - Abstract #EP-0911; "Aim/Introduction: To evaluate the safety profile and therapeutic efficacy of dose-escalated ¹⁷⁷Lu PSMA-617 therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) post-taxane therapy, and to establish optimal dosing strategies by investigating whether higher activity doses (>200 mCi) can be safely administered without exceeding dose thresholds to critical organs including salivary glands, kidneys, and bone marrow... Preliminary experience indicates that dose-escalated ¹⁷⁷Lu PSMA therapy beyond conventional 7.4 GBq dosing is feasible and safe with improved objective response rates at higher activities (280-300 mCi/dose). Critical organ doses remain well below established thresholds. These findings support further investigation of optimized, individualized dosing strategies to maximize therapeutic benefit while maintaining acceptable toxicity profiles in mCRPC patients."
Clinical • Metastases • Castration-Resistant Prostate Cancer • Dental Disorders • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Xerostomia
|
|
D. Malik; I. Sen; P. Thakral; A. Uppal; J. Gupta
|